aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
![GlobeNewswire](../../../Content/images/providers/GN.png)
aTyr Pharma, Inc. (LIFE)
Last atyr pharma, inc. earnings: 3/26 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
atyrpharma.com/investors-media
Company Research
Source: GlobeNewswire
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024. Ended the first quarter 2024 with $87.7 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2024 results and provided a corporate update. “During the first quarter of 2024 we continued to execute on our two clinical studies for our lead therapeutic candidate, efzofitimod, in interstitial lung disease (ILD),” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “We are pleased with the study conduct and quality to date for our global pivotal Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis, a major form of ILD wit
Show less
Read more
Impact Snapshot
Event Time:
LIFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIFE alerts
High impacting aTyr Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
LIFE
News
- Timothy Coughlin Bought 833% More Shares In aTyr Pharma [Yahoo! Finance]Yahoo! Finance
- aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR” [Yahoo! Finance]Yahoo! Finance
- aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”GlobeNewswire
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
LIFE
Earnings
- 3/14/24 - Miss
LIFE
Sec Filings
- 6/6/24 - Form 4
- 6/3/24 - Form 4
- 6/3/24 - Form 4
- LIFE's page on the SEC website